Margit Kapas - Publications

Lack of Clinically Meaningful Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive.

Journal: Neurology and therapy

Published: October 03, 2024

Population Pharmacokinetics of Cariprazine and its Major Metabolites.

Journal: European journal of drug metabolism and pharmacokinetics

Published: November 03, 2020

Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms

Journal: Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology

Published: September 21, 2019

Comment on: "Clinical Pharmacokinetics of Atypical Antipsychotics: An Update".

Journal: Clinical pharmacokinetics

Published: July 12, 2019

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania.

Journal: Clinical and translational science

Published: June 27, 2019

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).

Journal: Drug design, development and therapy

Published: February 03, 2016

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Journal: Psychopharmacology

Published: October 27, 2015

Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

Journal: Bioorganic & medicinal chemistry letters

Published: February 06, 2012